Predict your next investment

HEALTHCARE | Pharmaceutical Distribution & Wholesale
cranach-pharma.de

See what CB Insights has to offer

Stage

Acquired | Acquired

Valuation

$0000 

About Cranach Pharma

Cranach Pharma operates as a pharmaceutical wholesaler based in Germany.On December 4, 2020 Cranach Pharma was acquired by Medios at a valuation of $146.6M.

Cranach Pharma Headquarter Location

Luruper Chaussee 125

Hamburg Bahrenfeld, 22761,

Germany

040. 819 556 34

Latest Cranach Pharma News

Medios AG: Successful completion of the Cranach Pharma acquisition - Market position strengthened significantly

Jan 21, 2021

Medios AG: Successful completion of the Cranach Pharma acquisition - Market position strengthened significantly DGAP-News: Medios AG / Key word(s): Takeover/Expansion 21.01.2021 / 16:20 Press Release Medios AG: Successful completion of the Cranach Pharma acquisition - Market position strengthened significantly Berlin, 21 January 2021 - Today, Medios successfully completed the takeover of the specialized pharmaceutical wholesaler Cranach Pharma GmbH, Hamburg. With the entry of the capital increase in kind in the commercial register, all closing conditions have now been fulfilled, meaning that the acquisition is completed. The German Federal Cartel Office had already granted clearance on 21 December 2020. As a result, Medios is now the largest provider of Specialty Pharma solutions in Germany. Through the merger with Cranach Pharma GmbH, Medios' partner network has grown from around 330 to around 500 specialized pharmacies. For the 2021 financial year, Medios expects, including the acquired Cranach Pharma GmbH, a significant increase in group sales to more than €1 billion. Matthias Gärtner, Chairman of the Executive Board and Chief Financial Officer of Medios AG: "We are pleased to add our long-standing partner, Cranach Pharma, to the Medios Group. The acquisition strengthens our position as a full-service provider of Specialty Pharma solutions and gives us the opportunity to leverage an even broader product offering, as well as synergies in purchasing, sales and logistics. Our goal is to grow both organically and inorganically. We are well prepared for further acquisitions." The seller of Cranach Pharma GmbH is BMSH GmbH, which already holds a stake in Medios. The purchase price was paid in the form of 4,180,000 new Medios shares, which were created from authorized capital within a capital increase against contribution in kind. This is approximately 20.6% of the Medios share capital, after implementation of the capital increase. The purchase price for Cranach Pharma thus amounts to roughly €120.8 million based on a share price of approximately €28.90 per share. As a result, the share capital of Medios AG has increased from €16,084,991 to €20,264,991. Existing shareholdings of shareholders are reduced accordingly, so that reporting thresholds may also be undercut and voting rights notifications may become necessary. The new shares are subject to staggered lock-up periods of up to 24 months. As part of the acquisition, Medios will provide Cranach Pharma with funding of approximately €30 million to strengthen its working capital and finance further growth. ------------------- About Medios AG Medios AG is the leading provider of Specialty Pharma solutions in Germany. As a competence partner and expert, Medios covers all relevant aspects of the supply chain in this field: from pharmaceutical supply and the manufacture of patient-specific therapies to drug safety, including blistering. The focus is on optimal patient care via specialized pharmacies. Medios AG is Germany's first listed Specialty Pharma company and member of the SDAX selection index. The shares (ISIN: DE000A1MMCC8) are listed on the Regulated Market of the Frankfurt Stock Exchange (Prime Standard). Kirchhoff Consult AG P +49 40 609 186 18 nikolaus.hammerschmidt@kirchhoff.de Disclaimer This notification contains forward-looking statements that are subject to certain risks and uncertainties. Future results may significantly deviate from currently expected results, specifically due to various risk factors and uncertainties such as changes in business, economic, and competitive circumstances, exchange rate fluctuations, uncertainties about legal disputes or investigations, and the availability of financial resources. Medios AG assumes no responsibility whatsoever for updating the forward-looking statements contained in this notification. 21.01.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.